| dc.contributor.author | Crundwell, Malcolm | |
| dc.date.accessioned | 2020-05-12T13:43:24Z | |
| dc.date.available | 2020-05-12T13:43:24Z | |
| dc.date.issued | 2020-02 | |
| dc.identifier.citation | Huddart RA [et al]. Patient-reported Quality of Life outcomes in patients treated for muscle-invasive bladder cancer with radiotherapy ± chemotherapy in the BC2001 Phase III Randomised Controlled Trial. European Urology. 2020 Feb;77(2):260-268 | en_US |
| dc.identifier.pmid | 31843338 | |
| dc.identifier.doi | 10.1016/j.eururo.2019.11.001 | |
| dc.identifier.uri | https://rde.dspace-express.com/handle/11287/621272 | |
| dc.description.abstract | BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer, demonstrated improvement of local control and bladder cancer-specific survival from the addition of concomitant 5-fluorouracil and mitomycin C to radiotherapy. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier | en_US |
| dc.relation.url | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31843338/ | en_US |
| dc.rights | This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) | en_US |
| dc.subject | Wessex Classification Subject Headings::Urology | en_US |
| dc.title | Patient-reported Quality of Life outcomes in patients treated for muscle-invasive bladder cancer with radiotherapy ± chemotherapy in the BC2001 Phase III Randomised Controlled Trial | en_US |
| dc.type | Journal Article | en_US |
| dc.type | Randomized Controlled Trial | en_US |
| dc.identifier.journal | European Urology | en_US |
| dc.identifier.pmcid | PMC6983941 | |
| dc.description.note | This article is available via Open Access. Click on the Publisher URL to access the full-text. | en_US |
| dc.type.version | Published | en_US |
